XENON PHARMACEUTICALS INC (XENE)
Health Care · Neuroscience biopharmaceuticals / CNS drug development · NASDAQ
A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and depression.
What XENON PHARMACEUTICALS INC does
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing innovative therapeutics for neurological and psychiatric disorders. The company's lead investigational candidate, azetukalner, is a Kv7 potassium channel opener in late-stage Phase 3 clinical development for epilepsy (focal onset seizures and primary generalized tonic-clonic seizures) and mood disorders (major depressive disorder and bipolar depression). The early-stage pipeline includes additional Kv7 potassium channel openers and Nav sodium channel modulators for high-need indications including pain.
Themes: ["Epilepsy treatment","Major depressive disorder (MDD) / mood disorders","Bipolar depression","Pain management","Potassium channel modulation","Sodium channel modulation","Neuropsychiatry"]
Fundamentals
- Price$70.96 as of 2026-07-09 close
- Market cap$6.1B as of 2026-07-10
- 1-year return+117.1% as of 2026-07-09 close
- Net margin-867.3% as of 2026-07-10
- ROE-49.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-7.3% as of 2026-07-10
- Revenue CAGR (3y)-77.8% SEC XBRL
- Beta0.63 as of 2026-07-10
Key risks (from latest filing)
["No approved products or product revenue to date; azetukalner's success depends entirely on Phase 3 trial outcomes and regulatory approval; company has accumulated deficit of $1.35 billion and expects continued significant losses for the foreseeable future.","Clinical development risk: Phase 3 studies may fail to meet primary efficacy endpoints or reveal safety/tolerability issues that prevent regulatory approval or commercialization.","Manufacturing and commercialization execution risk: company must establish appropriate manufacturing scale-up, navigate regulatory pathways with FDA/EMA, obtain reimbursement from payers, and build sales/marketing infrastructure—all requiring substantial capital investment with no guarantee of success."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.